ClinicalTrials.gg
Active, not recruitingNCT07107256Updated Oct 28, 2026

Clinical Trial of TQC2731 Injection in Patients With Chronic Sinusitis and Nasal Polyps

A Phase 3 interventional study of TQC2731 injection and Placebo of TQC2731 in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.. Active, not recruiting at 60 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

Updated Oct 28, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
8th of 43
246 · median 90
Started
2025
with 6 others
Phase 3
14 of 46
3 open now
Primary completion
2027-03
later than 13 of 23 live
Registered
32nd of 46
by date

Among the 46 studies in Nasal Polyps with a site in China, this one is the 8th largest by enrollment of the 43 interventional ones that give a count, is one of 7 that started in 2025, is one of 14 in phase 3, reaches primary completion later than 13 of the 23 other live ones, and was the 32nd registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

TQC2731 injection is a humanized monoclonal antibody that targets Thymic Stromal Lymphopoietin (TSLP), blocks the TSLP pathway, and inhibits the production of downstream cytokines, thereby exerting anti-inflammatory effects. The purpose of this study is to evaluate the efficacy and safety of TQC2731 injection in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed form prior to trial participation, demonstrating full understanding of trial objectives, procedures, and potential adverse reactions.
  • Age between 18 and 75 years (inclusive) at the time of informed consent signing, regardless of gender.
  • Diagnosis of bilateral chronic rhinosinusitis with nasal polyps (CRSwNP) meeting the diagnostic criteria of the "Chinese Guidelines for the Diagnosis and Treatment of Chronic Rhinosinusitis (2018)"
  • At least one prior course of systemic (prednisone 0.5-1 mg/kg/day or 15-30 mg/day or equivalent for minimum 5 days) within 2 years before screening, with persistent bilateral CRSwNP; AND/OR /intolerance to systemic corticosteroids; AND/OR prior nasal polyp surgery performed more than 6 months before screening.
  • Bilateral Nasal Polyp Score (NPS) ≥5 (maximum score 8) with ≥2 points per nostril, as assessed by nasal endoscopy during screening and randomization.
  • Nasal Congestion Score (NCS) ≥2 at screening (daily average) and randomization (weekly average).
  • Persistent symptoms of rhinorrhea and/or hyposmia/anosmia for over 8 weeks prior to screening.
  • 22-item Sino-Nasal Outcome Test (SNOT-22) score ≥30 at screening and randomization.
  • Stable dose of intranasal corticosteroids (INCS) for >4 weeks prior to screening (subjects using non-mometasone furoate nasal spray [MFNS] products must agree to switch to Mometasone Furoate Nasal Spray (MFNS) during the study).
  • Subjects with comorbid asthma must have had stable asthma symptoms for ≥4 weeks prior to screening (if using medications, such as inhaled corticosteroids, the same dose must have been stably maintained for ≥4 weeks before screening, and the dose is assessed to remain stable during the first phase).
  • The evaluation during the lead-in period showed that the medication adherence to intranasal mometasone furoate nasal spray (MFNS) was greater than 70%, and the adherence to daily symptom assessment records in the subjects' electronic logs was also greater than 70%. Note: Days with missing electronic log data were considered non-adherent to this criterion.
  • Agreement to practice effective non-pharmacologic from informed consent until 6 months post-final dose, for subjects/partners of .

Exclusion criteria

Exclusion Criteria:

  • Conditions/Diseases Affecting Efficacy Evaluation

    • Nasal septum deviation causing ≥1 nostril obstruction;
    • Perforation of the nasal septum
    • Acute sinusitis, nasal infection, or upper respiratory infection within 2 weeks pre-screening or during screening/run-in periods;
    • Rhinitis medicamentosa;
    • Eosinophilic granulomatosis with polyangiitis (EGPA), granulomatosis with polyangiitis (GPA), Young's syndrome, Kartagener's syndrome, other ciliary dyskinesia syndromes, or cystic fibrosis;
    • Suspected or confirmed fungal sinusitis by imaging;
    • Prior nasal surgery altering lateral wall structure precluding NPS assessment;
    • Nasal or benign tumors (e.g., papilloma, hemangioma);
  • Any intranasal and/or sinus surgery (including polypectomy) within 6 months prior to screening.
  • Uncontrolled epistaxis within 2 months prior to screening.
  • Regular use of decongestants (topical or systemic) prior to screening, except for short-term use during endoscopic examinations.
  • Patients who have received any of the following treatments prior to randomization:

    • Treatment with (including but not limited to: cyclophosphamide, cyclosporine, interferon gamma, azathioprine, methotrexate, mycophenolate, tacrolimus, Secukinumab) within 8 weeks or 5 half-lives prior to screening (whichever is longer);
    • Treatment with any monoclonal antibodies (including but not limited to: benralizumab, mepolizumab, omalizumab, dupilumab, or other similar drugs [e.g., TSLP blockers]) within 8 weeks or 5 half-lives prior to screening (whichever is longer).
    • Patients who used medium- or short-acting systemic (SCS, including oral, intravenous, or intramuscular administration), systemic traditional Chinese medicine preparations for treating CRS within 4 weeks prior to screening, or received long-acting SCS (e.g., triamcinolone acetonide injection) within 6 weeks prior to screening, or who plan to receive the aforementioned medications during the study period.
    • Use of corticosteroid-eluting nasal stents within 6 months prior to screening;
    • Treatment with immunoglobulins or blood products within 28 days prior to screening;
    • Administration of within 28 days prior to screening or planned during the study period;
    • Allergen-specific immunotherapy within 6 months prior to screening (allowed only if: initiated >3 months before screening, maintained at a stable dose for ≥1 month before Visit 1, and no planned dose changes during the study);
    • Participation in other drug/medical device clinical trials within 3 months prior to screening (based on last administration/use).
    • Use nasal antihistamines (such as olopatadine nasal spray, azelastine nasal spray, levocabastine nasal spray, etc.) for the first 3 days.
  • Screening for a history of active pulmonary tuberculosis within the past 12 months;
  • Exclusion of infections within the last 14 days requiring systemic antibiotic, antiviral, antifungal, antiparasitic, or antiprotozoal therapy;
  • Exclusion of subjects diagnosed with helminthic parasitic infection in the past 6 months who either did not receive standard treatment or had treatment failure;
  • Known or suspected history of immunosuppression, immune dysfunction, or immune dysregulation, including but not limited to invasive opportunistic infections (histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, aspergillosis), even if the infection has resolved; Or there is an unusual frequency, recurrence, or prolonged infection (as judged by the investigator).
  • The (FEV1) of the subjects during the screening/introduction period was ≤ 50% of the normal predicted value.
  • Patients with comorbid asthma who meet any of the following criteria:

Asthma exacerbation within 90 days before screening, or current use of inhaled corticosteroids (ICS) at a daily dose higher than 1000μg fluticasone (or equivalent).

Definition of Asthma Acute Exacerbation:

  • Use of systemic corticosteroids (or a temporary increase in the stable dose of baseline OCS) for at least 3 consecutive days due to worsening asthma; a single injection of depot long-acting corticosteroids may be considered equivalent to a 3-day course of systemic corticosteroids.
  • An emergency department or urgent care center visit due to asthma requiring systemic corticosteroids (as described above) (defined as evaluation and treatment in the emergency department or urgent care center lasting \<24 hours).
  • Hospitalization due to asthma (defined as admission to a medical facility and/or evaluation and treatment in a healthcare setting lasting ≥24 hours).

    • Use of leukotriene antagonists/modulators prior to randomization (subjects who have been on a stable dose of leukotriene modulators for ≥30 days continuously prior to randomization may be enrolled);
    • Presence of other concurrent active or respiratory diseases that, in the investigator's judgment, may significantly impact the study, such as active tuberculosis, lung cancer, bronchiectasis, pulmonary sarcoidosis, pulmonary fibrosis, pulmonary hypertension, interstitial lung disease, or other active pulmonary conditions
    • Subjects who have undergone lobectomy or lung volume reduction surgery within 12 months prior to the start of the study;
    • Exclusion of subjects with cardiovascular conditions (including but not limited to unstable ischemic heart disease, heart failure, uncontrolled hypertension, myocardial infarction, significant arrhythmias, long syndrome, or Fridericia-corrected QT interval (QTcF) prolongation [≥450 ms in men, ≥470 ms in women]) if the investigator deems participation could compromise safety or study outcome interpretation;
    • Exclude individuals with difficult venous access or a history of vasovagal syncope (needle/blood-related);
    • Exclusion of any current active malignancy or history of malignancy (Patients with basal cell carcinoma, localized squamous cell carcinoma of the skin, or carcinoma in situ of the cervix are eligible if curative treatment was completed >12 months before V1. Patients with other malignancies are eligible if curative treatment was completed at least 5 years before V1).
    • Presence of active diseases (including but not limited to Hashimoto's thyroiditis with hyperthyroidism, Graves' disease, inflammatory bowel disease, primary biliary cholangitis, systemic lupus erythematosus, multiple sclerosis and other neuroinflammatory disorders, psoriasis vulgaris, and rheumatoid arthritis);
    • Exclusion if any infectious disease screening indicator meets the following criteria during screening;
  • Exclusion of subjects who are positive for virus surface antigen (HBsAg).
  • Hepatitis B virus core antibody (HBcAb) with detectable Hepatitis B Virus (HBV)-DNA.
  • Exclude if Virus (HCV) antibody-positive and HCV-RNA positive, or if previously treated for HCV (regardless of current HCV-RNA status).
  • Anti-Treponema pallidum antibody (Anti-TP) positive (if syphilis serology is positive, a non-treponemal test must be performed; subjects with a negative non-treponemal test and deemed by the investigator as previously cured are eligible).
  • Anti- positive

    • Abnormal laboratory test results:
  • White blood cell count \<3.5 × 10⁹/L;
  • (AST) >2.5 × (ULN);
  • Alanine aminotransferase (ALT) >2.5 × ULN;
  • Total >2 × ULN;
  • Creatinine >1.5 × ULN

    • Any clinically significant abnormal findings during the import period, including physical examination, vital signs, 12-lead , blood biochemistry, hematology, or urinalysis, which in the investigator's judgment may place the patient at risk, affect study results, or impair the patient's ability to complete the entire study
    • Women who are pregnant or lactating.
    • Those who were still smokers or had quit smoking for less than six months at the time of screening.
    • Exclude those with regular excessive alcohol consumption (>14 units/week for females or >21 units/week for males) in the past 6 months, inability to abstain during the trial, or a positive breath alcohol test.
    • History of drug abuse within the past 2 years, or a positive drug abuse screening result.
    • Subjects with a known history of or allergic reaction to any ingredient of mometasone furoate nasal spray (Nasonex®) or TQC2731 injection.
    • Exclusion for any history of systemic allergic reaction to biologic agents (local injection site reactions excluded).
    • The participant demonstrated poor adherence and was deemed unable to complete the study.
    • Any medical or psychiatric condition that, in the judgment of the investigator or the sponsor's medical reviewer, may affect the subject's safety throughout the study or impede the subject's ability to complete the entire study process or interfere with the interpretation of study results, including but not limited to cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematologic disorders, psychiatric illnesses, or major physical disabilities.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
246 participants (actual)

Study arms

  • Active comparator
    TQC2731 injection

    TQC2731 injection/placebo,4 weeks as a treatment cycle.

    Drug: TQC2731 injection

  • Placebo comparator
    Placebo of TQC2731

    TQC2731 injection/placebo,4 weeks as a treatment cycle.

    Drug: Placebo of TQC2731

Interventions

  • TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.

  • DrugPlacebo of TQC2731

    TQC2731 injection is a humanized monoclonal antibody that targets TSLP, blocks the TSLP signaling pathway, inhibits the production of downstream cytokines, and exerts anti-inflammatory effects.

06

What researchers measure

Primary outcomes

  1. Nasal Polyp Score (NPS)

    Change in Nasal Polyp Score (NPS) from baseline to Week 24 in CRSwNP subjects.

    Time frame: From baseline to Week 24

  2. Nasal Congestion Score (NCS)

    Change in Nasal Congestion Score (NCS) from baseline to Week 24 in CRSwNP subjects

    Time frame: From baseline to Week 24

  3. Change in nasal polyp score (NPS) from baseline

    Change in nasal polyp score (NPS) from baseline at week 24 in ECRSwNP subjects.

    Time frame: From baseline to Week 24

  4. Change from baseline in Nasal Congestion Score (NCS)

    Change from baseline in Nasal Congestion Score (NCS) at Week 24 in ECRSwNP subjects

    Time frame: From baseline to Week 24

Secondary outcomes

  1. Lund-Mackay score

    The change in Lund-Mackay score from baseline for the subject's CT scan at week 24. The higher the score, the more severe the CRS condition.

    Time frame: From baseline to Week 24

  2. Olfactory loss score

    The change in anosmia score assessed in the electronic logs of subjects at each visit point relative to baseline. A reduction in the olfactory loss score implies therapeutic efficacy or ongoing recovery.

    Time frame: From baseline to Week 60

  3. 22-item Sino-Nasal Outcome Test (SNOT-22) score

    The change from baseline in the 22-item Sino-Nasal Outcome Test (SNOT-22) score at each visit.

    Time frame: From baseline to Week 60

  4. Total Symptom Score (TSS)

    The change in Total Symptom Score (TSS) from baseline at each visit point for the subjects. A reduction in the Total Nasal Symptom Score (TSS) post-treatment suggests effective therapeutic response.

    Time frame: From baseline to Week 60

  5. Visual Analog Scale (VAS)

    Visual Analog Scale (VAS) overall score changes for sinusitis relative to baseline at each visit point for subjects. A higher VAS score indicates a greater impact of sinusitis on the subject's quality of life.

    Time frame: From baseline to Week 60

  6. The proportion of subjects receiving systemic corticosteroid (SCS) rescue or nasal polyp (NP) surgery

    The proportion of subjects receiving systemic corticosteroid (SCS) rescue or nasal polyp (NP) surgery during the 24-week double-blind treatment period

    Time frame: From baseline to Week 24

  7. Time to systemic corticosteroid (SCS) rescue therapy or nasal polyp (NP) surgery

    Time to systemic corticosteroid (SCS) rescue therapy or nasal polyp (NP) surgery during the 24-week double-blind treatment period.

    Time frame: From baseline to Week 24

  8. Numbers of participants with adverse events (AEs) and abnormal laboratory test results

    Evaluate the safety of TQC2731 in subjects with CRSwNP, including abnormalities such as adverse events (AEs), laboratory tests, physical examinations, vital signs, and 12-lead electrocardiogram (ECG).

    Time frame: From baseline until 30 days after the last dose

  9. Incidence of anti-drug antibodies (ADA)

    Incidence of anti-drug antibodies (ADA)

    Time frame: 2 hours pre-dose in Day 1, Day 57, Day 169, Day 253, Day 365, Day 421 and at the time of withdrawal

  10. Incidence of neutralizing antibodies (Nab)

    Incidence of neutralizing antibodies (Nab)

    Time frame: 2 hours pre-dose in Day 1, Day 57, Day 169, Day 253, Day 365, Day 421 and at the time of withdrawal

  11. Blood eosinophil count

    Evaluate the changes from baseline in blood eosinophil count at each visit point.

    Time frame: 2 hours pre-dose in Day 1, Day 169, Day 365, Day 421 and at the time of withdrawal

  12. Total Immunoglobulin E (IgE) concentration

    Evaluate the changes from baseline in peripheral blood total IgE at each visit point.

    Time frame: 2 hours pre-dose in Day 1, Day 169, Day 365, Day 421 and at the time of withdrawal

  13. Nasal biopsy tissue eosinophil levels

    Evaluate the changes from baseline in nasal biopsy tissue eosinophil levels at each visit point.

    Time frame: 2 hours pre-dose in Day 1, Day 169, Day 365, Day 421 and at the time of withdrawal

  14. Change in nonECRSwNP nasal polyp score (NPS) from baseline

    Change in nonECRSwNP nasal polyp score (NPS) from baseline at Week 24

    Time frame: From baseline to Week 24

  15. The change from baseline in nonECRSwNP nasal congestion score (NCS)

    The change from baseline in nonECRSwNP nasal congestion score (NCS) at week 24

    Time frame: Week 24

  16. The percentage of subjects with an NPS score improvement of ≥1 point from baseline

    The percentage of subjects with an NPS score improvement of ≥1 point from baseline at each evaluation visit point.

    Time frame: Baseline through week 60

  17. The percentage of subjects with an NPS score improvement of ≥2 points from baseline

    The percentage of subjects with an NPS score improvement of ≥2 points from baseline at each evaluation visit point.

    Time frame: Baseline through week 60

  18. The percentage of subjects with an improvement of ≥1 point in NCS score compared to baseline

    The percentage of subjects with an improvement of ≥1 point in NCS score compared to baseline at each evaluation visit point.

    Time frame: Baseline through week 60

  19. The percentage of subjects with an improvement of ≥2 points in NCS score

    The percentage of subjects with an improvement of ≥2 points in NCS score at each evaluation visit compared to baseline.

    Time frame: Baseline through week 60

07

Study locations

60 sites
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Mar 2027, 18 months after the start.

Of 30 industry-sponsored phase 3 interventional studies under Nasal Polyps, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's planned 18 months is below that.

Counting every sponsor, half of 34 studies reached it within 22 months; a quarter within 19 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2025
First posted
Aug 6, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Sep 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07107256
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Sep 25, 2025
Primary completion
Mar 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 28, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQC2731

Start the discussion